环磷酰胺治疗自身免疫性皮肤病中国专家共识

doi:10.35541/cjd.20210039

摘要/Abstract

摘要： 【摘要】环磷酰胺是一种广谱抗肿瘤药，同时也作为免疫抑制剂，用于治疗多种自身免疫性皮肤病，如系统性红斑狼疮、皮肌炎、硬皮病、天疱疮、类天疱疮等。本共识对环磷酰胺的作用机理、在免疫性皮肤病中的适应证及用法用量、不良反应及注意事项及其在特殊人群的使用等进行规范总结，为皮肤科及相关专业医生规范应用环磷酰胺治疗免疫相关性皮肤病提供参考依据。

关键词: 环磷酰胺, 治疗, 红斑狼疮, 系统性, 皮肌炎, 硬皮病, 系统性, 自身免疫性皮肤病, 专家共识

Abstract: 【Abstract】 Cyclophosphamide is a broad-spectrum antineoplastic drug, and is also used as an immunosuppressant for the treatment of a variety of autoimmune skin diseases, such as systemic lupus erythematosus, dermatomyositis, scleroderma, pemphigus and pemphigoid. This consensus summarizes the mechanism of action, indications, usage and dosage of cyclophosphamide, adverse reactions and cautions during the treatment of immune skin diseases with it, as well as its application in special populations. It is hoped that this consensus will provide a reference for physicians in dermatology and relevant specialities in rational application of cyclophosphamide in the treatment of immune-related skin diseases.

Key words: Cyclophosphamide, Therapy, Lupus erythematosus, systemic, Dermatomyositis, Scleroderma, systemic, Autoimmune skin diseases, Expert consensus

中国医师协会皮肤科医师分会自身免疫性疾病学组. 环磷酰胺治疗自身免疫性皮肤病中国专家共识[J]. 中华皮肤科杂志, 2021, 54(9): 765-770.doi:10.35541/cjd.20210039

Autoimmune Disease Group, China Dermatologist Association. Chinese expert consensus on cyclophosphamide for the treatment of autoimmune dermatoses[J]. Chinese Journal of Dermatology, 2021, 54(9): 765-770.doi:10.35541/cjd.20210039

参考文献 36

［1］	Madondo MT, Quinn M, Plebanski M. Low dose cyclophospha⁃mide: mechanisms of T cell modulation［J］. Cancer Treat Rev, 2016,42:3⁃9. doi: 10.1016/j.ctrv.2015.11.005.
［2］	Christine Lutsiak ME, Semnani RT, Pascalis RD, et al. Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low⁃dose cyclophosphamide［J］. Blood,2005,105（7）:2862⁃2868. doi: 10.1182/blood⁃2004⁃06⁃2410.
［3］	Viaud S, Flament C, Zoubir M, et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients［J］. Cancer Res,2011,71（3）:661⁃665. doi: 10.1158/0008⁃5472.CAN⁃10⁃1259.
［4］	Yue Y, Song ZL, Li JH, et al. Posttransplant cyclophosphamide for HLA⁃haploidentical transplantation in patients with mucopolysaccharidosis［J］. J pediatr Hematol Oncol, 2018,40（6）:e350⁃e354. doi: 10.1097/MPH.0000000000001157.
［5］	Liu HY, Yan YL, Zhang FL, et al. The immuno⁃enhancement effects of tubiechong （eupolyphaga sinensis） lyophilized powder in cyclophosphamide⁃induced immunosuppressed mice［J］. Immunol Invest, 2019,48（8）:844⁃859. doi: 10.1080/08820139. 2019.1588291.
［6］	中国狼疮肾炎诊断和治疗指南编写组. 中国狼疮肾炎诊断和治疗指南［J］. 中华医学杂志, 2019,99（44）:3441⁃3455. doi: 10.3760/cma.j.issn.0376⁃2491.2019.44.001.
［7］	Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus［J］. Ann Rheum Dis, 2019,78（6）:736⁃745. doi: 10.1136/annrheumdis⁃2019⁃215089.
［8］	中华医学会风湿病学分会. 多发性肌炎和皮肌炎诊断及治疗指南［J］. 中华风湿病学杂志, 2010,14（12）:828⁃831. doi: 10.3760/cma.j.issn.1007⁃7480.2010.12.008.
［9］	Yang SH, Chang C, Lian ZX. Polymyositis and dermatomyositis ⁃ challenges in diagnosis and management［J］. J Transl Autoimmun, 2019,2:100018. doi: 10.1016/j.jtauto.2019.100018.
［10］	吴炜, 邓丹琪. 多发性肌炎/皮肌炎治疗研究进展［J］. 中国皮肤性病学杂志, 2020,34（3）:338⁃342. doi: 10.13735/j.cjdv.1001⁃7089.2019.03.034
［11］	Kowal⁃Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis［J］. Ann Rheum Dis, 2017,76（8）:1327⁃1339. doi: 10.1136/annrheumdis⁃2016⁃209909.
［12］	Kersten BE, den Broeder N, van den Hoogen F, et al. Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis［J］. Rheumatology （Oxford）, 2020,59（7）:1550⁃1555. doi: 10.1093/rheumatology/kez487.
［13］	鲁静浩, 李明. 系统性硬皮病相关间质性肺病的药物治疗进展［J］. 复旦学报（医学版）, 2018,45（5）:740⁃743,747. doi: 10.3969/j.issn.1672⁃8467.2018.05.023.
［14］	Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts［J］. J Am Acad Dermatol, 2020,82（3）:575⁃585. doi: 10.1016/j.jaad.2018.02.021.
［15］	Amagai M, Tanikawa A, Shimizu T, et al. Japanese guidelines for the management of pemphigus［J］. J Dermatol, 2014,41（6）:471⁃486. doi: 10.1111/1346⁃8138.12486.
［16］	中国医疗保健国际交流促进会皮肤科分会. 寻常型天疱疮诊断和治疗专家建议（2020）［J］. 中华皮肤科杂志, 2020,53（1）:1⁃7. doi: 10.35541/cjd.20190703.
［17］	中国医师协会皮肤科医师分会自身免疫性疾病亚专业委员. 大疱性类天疱疮诊断和治疗的专家建议［J］. 中华皮肤科杂志, 2016,49（6）:384⁃387. doi: 10.3760/cma.j.issn.0412⁃4030. 2016.06.003.
［18］	陈喜雪, 丁治云, 王明悦, 等. 米诺环素和烟酰胺联合小剂量糖皮质激素治疗62例大疱性类天疱疮［J］. 临床皮肤科杂志, 2015,44（12）:816⁃818.
［19］	中华医学会风湿病学分会. 白塞病诊断和治疗指南［J］. 中华风湿病学杂志, 2011,15（5）:345⁃347. doi: 10.3760/cma.j.issn. 1007⁃7480.2011.05.015.
［20］	Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet′s syndrome［J］. Ann Rheum Dis, 2018,77（6）:808⁃818. doi: 10. 1136/annrheumdis⁃2018⁃213225.
［21］	Abdelfattah⁃Hassan A, Shalaby SI, Khater SI, et al. Panax ginseng is superior to vitamin E as a hepatoprotector against cyclophosphamide⁃induced liver damage［J］. Complement Ther Med, 2019,46:95⁃102. doi: 10.1016/j.ctim.2019.08.005.
［22］	Zee RS, Mbanefo EC, Le LH, et al. IPSE, a parasite⁃derived host immunomodulatory protein, is a potential therapeutic for hemorrhagic cystitis［J］. Am J Physiol Renal Physiol, 2019,316（6）:F1133⁃F1140. doi: 10.1152/ajprenal.00468.2018.
［23］	Ponticelli C, Escoli R, Moroni G. Does cyclophosphamide still play a role in glomerular diseases?［J］. Autoimmun Rev, 2018,17（10）:1022⁃1027. doi: 10.1016/j.autrev.2018.04.007.
［24］	Iqubal A, Iqubal MK, Sharma S, et al. Molecular mechanism involved in cyclophosphamide⁃induced cardiotoxicity: old drug with a new vision［J］. Life Sci, 2019,218:112⁃131. doi: 10.1016/j.lfs.2018.12.018.
［25］	Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis［J］. N Engl J Med, 2005,353（21）:2219⁃2228. doi: 10.1056/NEJMoa043731.
［26］	Yanovsky RL, McLeod M, Ahmed AR. Treatment of pemphigus vulgaris: part 1 ⁃ current therapies［J］. Expert Rev Clin Immunol, 2019,15（10）:1047⁃1060. doi: 10.1080/1744666X.2020.1672535.
［27］	Schultz B, Hook K. Bullous diseases in children: a review of clinical features and treatment options［J］. Paediatr Drugs, 2019,21（5）:345⁃356. doi: 10.1007/s40272⁃019⁃00349⁃3.
［28］	Demir S, Sag E, Kaya Akca U, et al. The challenge of treating pulmonary vasculitis in Behçet disease: two pediatric cases［J］. Pediatrics, 2019,144（2）:e20190162. doi: 10.1542/peds.2019⁃0162.
［29］	Ujiie H, Iwata H, Yamagami J, et al. Japanese guidelines for the management of pemphigoid （including epidermolysis bullosa acquisita）［J］. J Dermatol, 2019,46（12）:1102⁃1135. doi: 10. 1111/1346⁃8138.15111.
［30］	Medhat BM, Behiry ME, Sobhy N, et al. Late⁃onset systemic lupus erythematosus: characteristics and outcome in comparison to juvenile⁃ and adult⁃onset patients⁃a multicenter retrospective cohort［J］. Clin Rheumatol, 2020,39（2）:435⁃442. doi: 10.1007/s10067⁃019⁃04776⁃y.
［31］	Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association⁃European Dialysis and Transplant Association （EULAR/ERA⁃EDTA） recommendations for the management of adult and paediatric lupus nephritis［J］. Ann Rheum Dis, 2012,71（11）:1771⁃1782. doi: 10.1136/annrheumdis⁃2012⁃201940.
［32］	房强, 陈伯权. 环磷酰胺对乙脑灭活疫苗和减毒活疫苗免疫效果的比较［J］. 中国医学科学院学报, 1989,（05）:317⁃321.
［33］	Hashmi K, Khan B, Ahmed P, et al. Allogeneic stem cell transplantation in chronic myeloid leukaemia⁃⁃2 1/2 year experience［J］. J Pak Med Assoc, 2005,55（11）:478⁃482.
［34］	Yang L, Yan C, Zhang F, et al. Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models［J］. Exp Anim, 2018,67（1）:71⁃82. doi: 10.1538/expanim.17⁃0048.
［35］	Chang TK, Yu L, Maurel P, et al. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P⁃450 inducers and autoinduction by oxazaphosphorines［J］. Cancer Res, 1997,57（10）:1946⁃1954.
［36］	Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose⁃effect relationship［J］. Clin Pharmacokinet, 1986,11（6）:483⁃504. doi: 10.2165/00003088⁃198611060⁃00005.

[1]	邱月棨付思祺罗帅寒天李亚萍张桂英. 2020年雄激素性脱发的研究进展[J]. 中华皮肤科杂志, 2021, 54(9): 835-838.
[2]	中华医学会医学美学与美容学分会激光美容学组中华医学会皮肤性病学分会美容激光学组中国医师协会美容与整形医师分会激光学组. 中国痤疮瘢痕治疗专家共识（2021）[J]. 中华皮肤科杂志, 2021, 54(9): 747-756.
[3]	中华医学会皮肤性病学分会皮肤肿瘤研究中心中国医师协会皮肤科医师分会皮肤肿瘤学组. 皮肤基底细胞癌诊疗专家共识（2021）[J]. 中华皮肤科杂志, 2021, 54(9): 757-764.
[4]	郭伟赵涛郭伟楠马翠玲高天文赵建红李冰. 早期甲黑素瘤115例手术治疗方案和预后回顾分析[J]. 中华皮肤科杂志, 2021, 54(9): 777-784.
[5]	王大光蒋佳怡. 几种甲病诊疗的思考[J]. 中华皮肤科杂志, 2021, 54(8): 733-737.
[6]	中华医学会皮肤性病学分会皮肤肿瘤研究中心中国医师协会皮肤科医师分会皮肤肿瘤学组. 皮肤鳞状细胞癌诊疗专家共识（2021）[J]. 中华皮肤科杂志, 2021, 54(8): 653-664.
[7]	宋歌梁官钊张美洁董嘉琤刘维达. 毳毛癣的临床诊治进展[J]. 中华皮肤科杂志, 2021, 54(8): 741-743.
[8]	杨骥徐欣植李明. 脂溢性皮炎样皮肌炎：一种特殊类型的皮肌炎[J]. 中华皮肤科杂志, 2021, 54(7): 639-641.
[9]	虞英媛李影余增洋郑建锋张希琳丁杨峰史玉玲. 英夫利西单抗治疗重度斑块状银屑病的疗效和安全性及其对PD-1、PD-L1表达的影响[J]. 中华皮肤科杂志, 2021, 54(7): 590-596.
[10]	张宇高迎霞顾宁琰朱虹陈京京胡清洁周敏段媛媛姚煦. 奥马珠单抗对慢性自发性荨麻疹患者的临床疗效和安全性分析[J]. 中华皮肤科杂志, 2021, 54(7): 582-585.
[11]	中华医学会皮肤性病学分会银屑病学组中华医学会皮肤性病学分会儿童学组. 中国儿童银屑病诊疗专家共识（2021）[J]. 中华皮肤科杂志, 2021, 54(7): 559-581.
[12]	杨长志张晓萍杨子良周乃慧朱丽萍邵凯朱婷婷余秀琴. 成人皮肌炎患者抗核抗体与临床特征及肿瘤风险的关系[J]. 中华皮肤科杂志, 2021, 54(6): 480-484.
[13]	梁高澎宋志强. 免疫球蛋白E型自身抗体在自身免疫相关皮肤病中的研究进展[J]. 中华皮肤科杂志, 2021, 54(6): 553-556.
[14]	曹珊杨宝琦. 疱疹样皮炎的研究进展[J]. 中华皮肤科杂志, 2021, 54(6): 549-553.
[15]	罗帅寒天龙海陆前进. 2020年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021, 54(6): 542-545.